 Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that a poster describing the design of the ongoing Phase III trial of BT5528 will be presented during an e-poster session at the American Society of Clinical Oncology ASCO 2020 Virtual Scientific Program on May 29-31, 2020. BT5528 is a second-generation Bicycle Toxin Conjugate BTC that targets EphA2, a tumor antigen that is overexpressed in a wide range of solid tumor types and is associated with poor outcomes. 